Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Rhea-AI Summary

Revelation Biosciences (NASDAQ:REVB) reported results for the three and nine months ended September 30, 2025, and disclosed corporate and cash updates.

Key points: the company announced top-line PRIME clinical study results, received $9.6 million gross from a September 2025 warrant inducement, and held $12.7 million cash as of September 30, 2025 (up from $6.5 million at December 31, 2024).

Operating highlights include $6.3 million net cash used in operating activities for the nine months ended September 30, 2025 (down from $14.6 million in 2024), a Q3 2025 net loss of $1.9 million (loss per share $(1.77)), and a nine‑month net loss of $6.4 million (loss per share $(9.76)). The company expects cash to fund operations through Q3 2026 and plans to meet with the FDA to align on Gemini’s registration path.

Positive

• Cash balance increased to $12.7M as of September 30, 2025
• Received $9.6M gross from September 2025 warrant inducement
• Net operating cash outflow fell to $6.3M for nine months
• Announced top-line PRIME clinical study results and FDA engagement

Negative

• Q3 2025 net loss of $1.9M (loss per share $(1.77))
• Nine-month net loss of $6.4M through September 30, 2025
• Cash runway limited to through Q3 2026 under current plans

Insights

Life Sciences & Finance Analyst

Positive operational progress: promising PRIME topline, fresh financing, and extended cash runway through third quarter of 2026.

The company disclosed groundbreaking top-line results from the PRIME clinical study and secured $9.6 million in gross proceeds from a warrant inducement in September 2025. Cash and cash equivalents rose to $12.7 million from $6.5 million at year-end 2024, and management states these funds are sufficient to support operations through Q3 2026. Recent operating cash burn improved to $6.3 million for the nine months ended September 30, 2025, down from $14.6 million a year earlier.

Risks and dependencies are explicit and narrow: the clinical data description lacks detail beyond a topline characterization, and regulatory alignment depends on an upcoming meeting with the FDA later this year per management comment. Reported losses narrowed—quarterly net loss $1.9 million (\$(1.77) per share) and nine-month net loss $6.4 million (\$(9.76) per share)—which reflect lower cash burn but do not by themselves confirm commercial or regulatory success.

Watch for the formal FDA meeting outcome and any disclosed primary endpoint data from PRIME as the immediate catalysts; the company’s stated cash runway to Q3 2026 is the key near-term liquidity metric to monitor.

SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and nine months ended September 30, 2025.

Corporate Highlights

• Announced Groundbreaking Top-line Results from PRIME Clinical Study

• Received gross proceeds of $9.6 million from warrant inducement in September 2025

"The outstanding PRIME data and subsequent financing validate Gemini's potential and places the company on solid footing to advance the next phase of development," said James Rolke, Chief Executive Officer of Revelation. "We look forward to meeting with the FDA later this year to gain agreement on the clinical development path to registration of Gemini, in turn enhancing shareholder value."

Results of Operations

As of September 30, 2025, Revelation had $12.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024. The increase in cash and cash equivalents was primarily due to net cash proceeds from the May 2025 public offering and the September 2025 warrant inducement, offset by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through the third quarter of 2026

Revelation's net cash used for operating activities for the nine months ended September 30, 2025 was $6.3 million compared to net cash used for operating activities of $14.6 million for the same period in 2024. Revelation's net loss for the three months ended September 30, 2025 was $1.9 million, or $(1.77) basic and diluted net loss per share compared to a net loss of $2.2 million, or $(40.15) basic and diluted net loss per share for the same period in 2024. Revelation's net loss for nine months ended September 30, 2025 was $6.4 million, or $(9.76) basic and diluted net loss per share compared to net loss of $13.3 million, or $(354.05) basic and diluted net loss per share for the same period in 2024.

About Gemini

Gemini is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD^®) that reduces the damage associated with inflammation by reprogramming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner.

Gemini has the potential to treat a wide range of acute and chronic inflammatory conditions. Our primary focus is on the treatment of acute kidney injury (Gemini-AKI) as there are currently no therapies available to treat the large AKI market, and we believe this acute condition will provide the shortest pathway to marketing approval. In addition to AKI, Gemini is being evaluated for the treatment of chronic kidney disease (GEMINI-CKD program), post-burn infection and hyper-inflammatory response (Gemini-PBI) and post-surgical infection (GEMINI-PSI program).

The potential of Gemini has been demonstrated in multiple preclinical studies, previously announced positive Phase 1 clinical data, and in the recently announced positive Phase 1b clinical data in CKD patients.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and for the treatment of chronic kidney disease.

For more information, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

REVELATION BIOSCIENCES, INC.
Consolidated Statements of Operations

		Three Months Ended September 30,								Nine Months Ended September 30,
		2025				2024				2025				2024
Operating expenses:
Research and development		$	922,857			$	830,981			$	3,099,667			$	2,943,492
General and administrative			1,020,154				965,705				3,399,559				3,277,729
Total operating expenses			1,943,011				1,796,686				6,499,226				6,221,221
Loss from operations			(1,943,011	)			(1,796,686	)			(6,499,226	)			(6,221,221	)
Other income (expense):
Change in fair value of warrant liability			611				6,041				2,071				78,884
Other income (expense), net			35,224				(450,920	)			94,512				(7,170,480	)
Total other income (expense), net			35,835				(444,879	)			96,583				(7,091,596	)
Net loss		$	(1,907,176	)		$	(2,241,565	)		$	(6,402,643	)		$	(13,312,817	)
Deemed dividends			(2,769,742	)			-				(5,951,528	)			-
Net loss attributable to common stockholders		$	(4,676,918	)		$	(2,241,565	)		$	(12,354,171	)		$	(13,312,817	)
Net loss per share, basic and diluted		$	(1.77	)		$	(40.15	)		$	(9.76	)		$	(354.05	)
Weighted-average shares used to compute net loss per share, basic and diluted			2,644,733				55,832				1,265,571				37,602

REVELATION BIOSCIENCES, INC.
Consolidated Balance Sheets

		September 30, 2025				December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents		$	12,708,489			$	6,499,018
Prepaid expenses and other current assets			123,934				66,699
Total current assets			12,832,423				6,565,717
Property and equipment, net			23,919				56,332
Total assets		$	12,856,342			$	6,622,049
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	1,034,951			$	783,621
Accrued expenses			819,381				1,127,800
Warrant liability			175				2,246
Total current liabilities			1,854,507				1,913,667
Total liabilities			1,854,507				1,913,667
Commitments and Contingencies (Note 4)
Stockholders' equity:
Common Stock, $0.001 par value; 500,000,000 shares authorized at September 30, 2025 and December 31, 2024 and 3,585,972 and 174,104 issued and outstanding at September 30, 2025 and December 31, 2024, respectively			3,586				174
Additional paid-in-capital			57,906,530				45,213,846
Accumulated deficit			(46,908,281	)			(40,505,638	)
Total stockholders' equity			11,001,835				4,708,382
Total liabilities and stockholders' equity		$	12,856,342			$	6,622,049

Company Contacts

Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Revelation Biosciences (REVB) announce on November 6, 2025?

REVB announced Q3 and nine‑month financial results, PRIME top‑line clinical results, and a September warrant inducement raising $9.6M gross.

How much cash did REVB have at September 30, 2025 and how long will it last?

REVB reported $12.7M cash and said it expects funds to support operations through Q3 2026 under current plans.

What was Revelation’s operating cash burn for the nine months ended September 30, 2025?

Net cash used in operating activities was $6.3M for the nine months ended September 30, 2025.

What were REVB’s reported net losses for Q3 2025 and nine months 2025?

Q3 2025 net loss was $1.9M (loss per share $(1.77)); nine‑month net loss was $6.4M (loss per share $(9.76)).

What corporate actions bolstered Revelation’s cash position in 2025?

Proceeds from a May 2025 public offering and a September 2025 warrant inducement (gross $9.6M) increased cash.

What regulatory step did REVB plan after the PRIME results?

The company plans to meet with the FDA later in 2025 to discuss the clinical development path to registration for Gemini.